ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.792,63
-0,25%
S&P 500
5.246,79
-0,58%
US Dollar vs BRL
5,23447
-0,23%
Bitcoin
69.207,26
2,15%
Brent Oil
78,435
-2,93%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Genelux Corporation (GNLX)

  7. Genelux Corporation (GNLX) Notícias

GNLX

Genelux (GNLX)

Genelux Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GNLX
DataHoraFonteTítuloCódigoCompanhia
24/05/202418:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNLXGenelux Corporation
24/05/202409:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNLXGenelux Corporation
24/05/202409:00GlobeNewswire Inc.Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsNASDAQ:GNLXGenelux Corporation
23/05/202417:01GlobeNewswire Inc.Genelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsNASDAQ:GNLXGenelux Corporation
15/05/202418:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNLXGenelux Corporation
09/05/202417:25GlobeNewswire Inc.Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
09/05/202417:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNLXGenelux Corporation
01/04/202408:00GlobeNewswire Inc.Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GNLXGenelux Corporation
14/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GNLXGenelux Corporation
02/02/202418:36Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GNLXGenelux Corporation
02/02/202418:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GNLXGenelux Corporation
15/12/202318:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GNLXGenelux Corporation
27/11/202309:00GlobeNewswire Inc.Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerNASDAQ:GNLXGenelux Corporation
14/11/202319:50GlobeNewswire Inc.Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
19/09/202318:37Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:GNLXGenelux Corporation
14/09/202308:00GlobeNewswire Inc.Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GNLXGenelux Corporation
13/09/202321:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GNLXGenelux Corporation
07/09/202317:01GlobeNewswire Inc.Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:GNLXGenelux Corporation
28/08/202308:00GlobeNewswire Inc.Genelux Corporation Announces New Chief Financial OfficerNASDAQ:GNLXGenelux Corporation
24/08/202317:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GNLXGenelux Corporation
14/08/202308:00GlobeNewswire Inc.Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
02/08/202317:00GlobeNewswire Inc.Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023NASDAQ:GNLXGenelux Corporation
20/07/202317:45GlobeNewswire Inc.Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New HiresNASDAQ:GNLXGenelux Corporation
20/07/202317:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:GNLXGenelux Corporation
20/07/202317:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:GNLXGenelux Corporation
29/06/202308:00GlobeNewswire Inc.Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLCNASDAQ:GNLXGenelux Corporation
29/06/202307:02Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:GNLXGenelux Corporation
22/06/202308:00GlobeNewswire Inc.Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023NASDAQ:GNLXGenelux Corporation
12/06/202308:00GlobeNewswire Inc.Genelux Corporation Announces $18 Million Private PlacementNASDAQ:GNLXGenelux Corporation
12/06/202307:44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GNLXGenelux Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:GNLX

Seu Histórico Recente

LSE
SSTY
Safestay
ASX
SOP
Synertec
ASX
AWNDD
Arowana
BIT
F21482
Vontobel Financial Produ...
LSE
TGI
NASDAQ
FAQVX
Franklin Moderate Alloca...
ASX
JYC
Joyce
LSE
UL07
Citi Fun 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados